Zacks Research Comments on Bausch Health Companies Inc.’s FY2023 Earnings (NYSE:BHC)

Bausch Health Companies Inc. (NYSE:BHCFree Report) – Analysts at Zacks Research raised their FY2023 earnings estimates for Bausch Health Companies in a report released on Monday, February 5th. Zacks Research analyst R. Department now anticipates that the company will earn $3.36 per share for the year, up from their prior forecast of $3.34. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.40 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2023 earnings at $1.00 EPS, Q2 2024 earnings at $0.90 EPS, FY2024 earnings at $3.71 EPS, Q1 2025 earnings at $0.89 EPS, Q2 2025 earnings at $0.92 EPS and FY2025 earnings at $4.17 EPS.

Separately, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday.

Read Our Latest Stock Analysis on Bausch Health Companies

Bausch Health Companies Stock Down 0.1 %

NYSE:BHC opened at $8.13 on Tuesday. The company’s fifty day moving average price is $7.83 and its 200-day moving average price is $7.91. Bausch Health Companies has a 1-year low of $5.57 and a 1-year high of $10.23. The firm has a market capitalization of $2.93 billion, a P/E ratio of -3.08 and a beta of 0.79. The company has a debt-to-equity ratio of 74.20, a current ratio of 1.20 and a quick ratio of 0.89.

Institutional Trading of Bausch Health Companies

A number of hedge funds have recently added to or reduced their stakes in BHC. Segantii Capital Management Ltd lifted its holdings in Bausch Health Companies by 20.0% during the third quarter. Segantii Capital Management Ltd now owns 3,000,000 shares of the company’s stock valued at $24,660,000 after purchasing an additional 500,000 shares in the last quarter. Whitebox Advisors LLC lifted its holdings in Bausch Health Companies by 325.8% during the second quarter. Whitebox Advisors LLC now owns 1,090,000 shares of the company’s stock valued at $8,720,000 after purchasing an additional 834,000 shares in the last quarter. Black Swift Group LLC purchased a new position in Bausch Health Companies during the third quarter valued at $411,000. National Bank of Canada FI lifted its holdings in Bausch Health Companies by 18.8% during the third quarter. National Bank of Canada FI now owns 15,661,724 shares of the company’s stock valued at $127,486,000 after purchasing an additional 2,480,084 shares in the last quarter. Finally, Money Concepts Capital Corp purchased a new position in Bausch Health Companies during the third quarter valued at $10,508,000. 74.56% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

(Get Free Report)

Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

Featured Stories

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.